Pacira BioSciences develops and commercializes non-opioid pain management products for surgical and other clinical settings. Its flagship product, EXPAREL, is a long-acting bupivacaine liposome injectable suspension used for postsurgical local analgesia. The company targets hospitals, ambulatory surgery centers, and clinicians seeking alternatives to opioid-based pain control.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 181.1 | — | -4.8 | — |
| Q3 2025 | 179.5 | — | 5.4 | — |
| Q4 2025 | 196.9 | — | 1.6 | — |
| Q1 2026 | 177.4 | — | 2.9 | — |
| Q2 2026 | 192.4 | 6.2% | 4.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Healthcare Services Group, Inc. (HCSG), MillerKnoll, Inc. (MLKN), United Fire Group, Inc. (UFCS), Lakeland Financial Corporation (LKFN), Quantum Computing Inc. (QUBT), Esquire Financial Holdings, Inc. (ESQ)